Ozempic May Lower Alzheimer's Risk in Type 2 Diabetics, Study Finds

A study suggests the diabetes drug semaglutide significantly reduces Alzheimer's risk compared to other medications.

Researchers at Case Western Reserve University analyzed electronic health records of nearly 1 million U.S. patients with Type 2 diabetes.
Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of Alzheimer's compared to seven other diabetes drugs.
The study found consistent results across different subgroups, including age, gender, and obesity status.
While promising, the findings are observational, and researchers emphasize the need for further clinical trials to confirm causality.
Novo Nordisk, the maker of Ozempic, is conducting its own trials to explore semaglutide's potential benefits for Alzheimer's patients.